curve guardian glp-1 LY3437943, a novel triple glucagon, GIP, and receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Harvard Business Review | A

10.3389/fphys.2019.00229 Front Physiol

Kurosu M, Kashimura K, Apparent usability vs

This comes as the American College of Cardiology (ACC) released its five top trends in cardiovascular medicine in 2025, including Anti-Obesity Drugs: Cardiovascular Benefit Beyond Weight Loss. The ACC reports that semaglutide and tirzepatide both demonstrate remarkable cardiovascular benefits that extend beyond weight management. Clinical trials show these medications can reduce the risk of major adverse cardiovascular events by up to 20% in patients with obesity and preexisting cardiovascular conditions

[DOI] [PubMed] [Google Scholar] 74.Liu Y.-S., Huang Z.-W., Wang L., et al